A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease
Table 1
Baseline characteristics according to the randomized groups. Median (25, 75 percentiles) or number is given.
Characteristics
Saxagliptin
Placebo
Age (years)
68.5 (63.0, 73.0)
64.0 (58.5, 67.5)
Number (female)
6 (0)
6 (1)
Years of diabetes
7.8 ± 4.4
9.2 ± 3.6
Years of CAD
6 (1, 15)
2 (1, 7)
Hypertension (n)
5
6
Previous AMI (n)
3
3
Current smoker (n)
2
1
SBP (mmHg)
128 (121, 144)
133 (123, 145)
DBP (mmHg)
75 (68, 79)
74 (69, 80)
Waist circumference (cm)
103 (90, 117)
105 (94, 110)
BMI (kg/m2)
28.1 (25.1, 32.3)
28.6 (24.7, 29.0)
Medication (n)
Glimepiride
2
1
Metformin
5
6
Platelet inhibitors
4
5
ACE-inhibitors or ARBs
4
6
Betablocker
5
6
Statin
6
6
Diuretic
3
1
AMI: acute myocardial infarction; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; ACE: angiotensin converting enzyme; ARB: angiotensin II receptor blocker.